Gene Therapy to Target CEA for Oncology is under clinical development by Chongqing Precision Biotech and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CEA for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CEA for Oncology overview

Gene-modified cell therapy is under development for the treatment of relapsed and refractory CEA positive malignant tumors, metastatic colorectal cancer, esophageal cancer, esophagogastric junction cancer, gastric cancer, HER 2 positive breast cancer, triple-negative breast cancer, cholangiocarcinoma (bile duct cancer), non-small cell lung cancer and metastatic pancreatic cancer. It is administered through intravenous route. The drug candidate comprises T cells modified to express chimeric antigen receptors (CART) acts by targeting carcinoembryonic antigen-expressing (CEA) tumors.

For a complete picture of Gene Therapy to Target CEA for Oncology’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.